Pharmaceuticals Global News & Press Release Distribution

Pharmaceuticals

All
APAC

CARsgen's Satri-cel Abstract Available on ASCO Website

SHANGHAI, May 22, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that an abstract of the research results of the confirmatory Phase II clinical trial of satricabtagene autoleucel ("satri-...

2025-05-23 08:00 2263

Porton Advanced Announces Collaboration with TongEYE to Accelerate Development of iPSC-RPEC transplantation therapy

SUZHOU, China, May 22, 2025 /PRNewswire/ -- Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with TongEye Medical Technology (TongEYE), an innovator focusing on...

2025-05-22 21:00 2198

Porton Advanced Announces Collaboration with TongEYE to Accelerate Development of iPSC-RPEC transplantation therapy

BioDlink Clinches Brazil GMP Audit to Strengthen Emerging Markets Growth

* International recognition of quality system with GMP-compliance in the key markets ofBrazil, Indonesia, Egypt, Colombia and Argentina * Passed its first-ever on-site PIC/S audit, reinforcing its strong commitment to stringent international regulatory standards * Demonstrated BioDlink's cap...

2025-05-21 20:30 2198

SK bioscience Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine

* No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 toRussia * Company plans to export PCV13 vaccine components * "We aim for the global PCV market with our 21-valent and next-generation pneumococcal vaccines currently...

2025-05-21 20:00 2602

SK bioscience Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine

Accropeutics Announces Positive Data from Phase 2 Trial of AC-201, an oral, selective TYK2/JAK1 Inhibitor, for the treatment of Moderate-to-Severe Plaque Psoriasis

* Phase 2 primary endpoint of PASI-75 and key secondary endpoints met in all of the three dosing groups at Week 12 * AC-201 was generally well tolerated at all dose levels with no SAEs or AEs leading to discontinuation * Efficacy and safety findings from this Phase 2 trial support advancing ...

2025-05-21 08:50 1731

Minghui Pharmaceutical Announces First Patient Dosed in the Phase Ⅱ Combination Study of PD-1xVEGF Bispecific and TROP-2 ADC in Advanced NSCLC

SHANGHAI, May 20, 2025 /PRNewswire/ -- Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative therapies in immunology and oncology, today announced that the first patient has been successfully dosed in a Phase Ⅱ clinical trial evaluating the safety a...

2025-05-20 18:18 3687

WuXi XDC Received Multiple Awards from 2025 Extel (previously "Institutional Investor") Ranking in Diverse Categories

SHANGHAI, May 19, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate market, today announced that the company received multiple top awards- "Best CEO", "Bes...

2025-05-20 09:44 3118

WuXi XDC Received Multiple Awards from 2025 Extel (previously

Porton Advanced Announces Collaboration with Hualong Biological to Accelerate MATC Cell Therapy Development for Solid Tumor Treatment Breakthroughs

SUZHOU, China, May 19, 2025 /PRNewswire/ -- Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Hualong Biological, an innovator in novel cancer therapeutics....

2025-05-19 21:00 2169

2025 EASL Congress Spotlight: CG-0416 Preclinical Data Unveils A Groundbreaking Dual-Action Therapy Targeting Obesity and MASH

——A First-in-Class Hydrolysis-Activated Liver-Targeted THR-β Prodrug Demonstrating A Dual Advantage of Fat Reduction and Muscle Preservation SHANGHAI, May 16, 2025 /PRNewswire/ -- At the European Association for the Study of the Liver (EASL) Annual Congress, CureGene Pharmaceuticals("CureGene") ...

2025-05-17 08:41 4003

SNS812, an innovative siRNA drug from Oneness and Microbio (Shanghai), selected for ATS 2025 oral presentation, demonstrating world-leading clinical outcomes in COVID-19 treatment

TAIPEI, May 16, 2025 /PRNewswire/ -- The broad-spectrum antiviral siRNA drug SNS812, co-developed by Oneness Biotech (4743.TW) and Microbio (Shanghai), has been selected for oral presentation at the prestigious 2025 American Thoracic Society (ATS) International Conference. The presentation will d...

2025-05-16 23:10 4444

Xuanzhu Biopharm's Xuanyuening® (BireociclibTablets) Approved for Dual Indications, Bringing Innovative Breakthroughs to Breast Cancer Treatment

HONG KONG, May 15, 2025 /PRNewswire/ -- On May 15, 2025, the latest announcement released by the National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market. Bireociclib tablets (trade name: Xuanyuening®), a Class 1 anti-tumor ne...

2025-05-16 11:57 2181

Dizal to Present Promising Clinical Data on Golidocitinib and DZD8586 for the Treatment of Lymphoma at the Coming International Hematology Conferences

* The latest 2-year follow-up data on golidocitinib as a maintenance therapy for peripheral T-cell lymphoma (PTCL) patients who achieved tumor response after first-line systemic therapy will be presented orally at the 2025 ICML * A pooled safety and efficacy analysis of two Phase I/II studies ...

2025-05-15 18:09 2495

Caliway Announces Successful EOP2 Meeting with the FDA for CBL-514 in Reduction of Abdominal Subcutaneous Fat

* Caliway has completed the End-of-Phase 2 (EOP2) meeting with the U.S. FDA for CBL-514, the world's first investigational drug for large-area subcutaneous fat reduction developed under the 505(b)(1) regulatory pathway. * The company has received the EOP2 meeting minutes, confirming the primar...

2025-05-14 13:38 2316

GC Biopharma Receives FDA Approval for its U.S. Plasma Collection Center in Calexico, California

YONGIN, South Korea, May 14, 2025 /PRNewswire/ -- GC Biopharma, a South Korean pharmaceutical company, announced that its U.S. subsidiary, ABO Holdings, has received FDA approval for its plasma collection center located inCalexico, California. Following the successful U.S. launch of ALYGLO (im...

2025-05-14 13:21 2172

iNtRON Seeks a Strategic Partner to Explore the Promising Market for MRSA Decolonization

* Aiming to Provide a Novel Solution Against Post-Operative MRSA Infections * Demonstrated its Efficacy and Safety through previous Clinical Trials * Company seeks global partners to co-develop toward Commercialization SEOUL, South Korea and BOSTON, May 13, 2025 /PRNewswire/ -- iNtRON Biotech...

2025-05-13 20:00 1925

Strategic Partnership | Sanyou Bio and TransRecoBio Forge Strategic Alliance to Build a New Ecosystem for the Full Industry Chain

SHANGHAI, May 13, 2025 /PRNewswire/ -- Recently, Sanyou Biopharmaceuticals ( Shanghai) Co., Ltd. ("Sanyou Biopharmaceuticals") and TransRecoBio (Wenzhou) Biotechnology Co., Ltd. ("TransRecoBio") officially signed a strategic cooperation agreement. The two companies will integrate their core streng...

2025-05-13 18:00 2277

Grit Biotechnology Presents Multiple Scientific Breakthroughs at ASGCT 2025 Annual Meeting

SHANGHAI, May 12, 2025 /PRNewswire/ -- Grit Biotechnology Co., Ltd. ("Grit Bio "), a clinical-stage biotech pioneering novel immunotherapies announced today that three research programs, in collaboration with Vitalgen BioPharma Co., Ltd. ("Vitalgen"), will be showcased in one oral presentation and...

2025-05-12 20:30 2407

CARsgen Announces Preliminary Clinical Data for Allogeneic BCMA CAR-T CT0596, Demonstrating Favorable Safety and Efficacy

SHANGHAI, May 11, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces preliminary clinical data for CT0596, an allogeneic BCMA-targeted CAR-T developed using the THANK-u Plus™ platform. CT0596...

2025-05-12 08:00 2368

Skyline Therapeutics Presents Late-Breaking Abstract on SKG1108, a Novel Optogenetic Gene Therapy for Retinitis Pigmentosa, at ASGCT 2025

SHANGHAI, May 10, 2025 /PRNewswire/ -- Skyline Therapeutics, an innovation-drivenclinical-stage gene therapy company focused on developing unique and novel solutions for rare and severe diseases, today announced a late-breaking abstract presentation onSKG1108, its investigational optogenetic gen...

2025-05-11 00:00 3971

Minghui Pharmaceutical Announces Strategic Partnership and Licensing Agreement with Qilu Pharmaceutical to Develop B7-H3 ADC in Greater China

SHANGHAI, May 9, 2025 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company, today announced an exclusive licensing and collaboration agreement with Qilu Pharmaceutical ("Qilu") for the development, manufacturing, and commercialization of its B7-H3 AD...

2025-05-09 18:00 7407

1 ... 24 25 262728 29 30 ... 153